M32: Systemic lupus erythematosus
GPTKB entity
Statements (53)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:disease
|
gptkbp:affects |
gptkb:skin
brain heart lungs kidneys joints immune system |
gptkbp:cause |
autoimmune disease
|
gptkbp:complication |
gptkb:cardiovascular_disease
gptkb:anemia thrombosis infections lupus nephritis neuropsychiatric lupus |
gptkbp:eponymOf |
Libman–Sacks endocarditis
Rowell's syndrome |
gptkbp:has_diagnostic_test |
gptkb:ANA_test
gptkb:anti-dsDNA_antibody_test urinalysis complement levels |
gptkbp:has_mortality_risk |
increased
|
gptkbp:has_OMIM_ID |
152700
|
gptkbp:has_Orphanet_ID |
536
|
gptkbp:has_parent_disease |
lupus erythematosus
|
gptkbp:has_UMLS_CUI |
C0024141
|
https://www.w3.org/2000/01/rdf-schema#label |
M32: Systemic lupus erythematosus
|
gptkbp:ICD-10_code |
gptkb:M32
|
gptkbp:is_chronic |
true
|
gptkbp:is_relapsing-remitting |
true
|
gptkbp:MeSH_ID |
D008180
|
gptkbp:prevalence |
more common in women
onset usually between ages 15 and 45 |
gptkbp:riskFactor |
genetic predisposition
female sex hormonal factors environmental triggers |
gptkbp:symptom |
fever
fatigue joint pain hair loss photosensitivity skin rash oral ulcers |
gptkbp:synonym |
SLE
systemic lupus |
gptkbp:treatment |
gptkb:NSAIDs
biologics corticosteroids immunosuppressants antimalarials |
gptkbp:bfsParent |
gptkb:ICD-10_Block_M30-M36:_Systemic_connective_tissue_disorders
|
gptkbp:bfsLayer |
7
|